Page 133 - Cardiac Nursing

t
ara
ara
t
p
p
p
q
7-1
7-1
q
ara
10.
q
A
Pa
M
M
Pa
g
g
g
09
09
A
e 1
M
10.
e 1
09
1
1
0:4
009
0 A
0 A
0:4
LWBK340-c04_
LWB
LWB K34 0-c 04_ pp097-110.qxd 30/06/2009 10:40 AM Page 109 Aptara
04_
0-c
K34
009
09
xd
xd
3
p
p
3
6/2
6/2
0/0
3
0/0
CHAP TER 4 / Genetics 109
117. Keavney, B., McKenzie, C., Parish, S., et al. (2000). Large-scale test of 137. Frosst, P., Blom, H. J., Milos, R., et al. (1995). A candidate genetic risk
hypothesised associations between the angiotensin-converting-enzyme factor for vascular disease: A common mutation in methylenetetrahy-
insertion/deletion polymorphism and myocardial infarction in about drofolate reductase. Natural Genetics, 10(1), 111–113.
5000 cases and 6000 controls. International Studies of Infarct Survival 138. Kang, S. S., Passen, E. L., Ruggie, N., et al. (1993). Thermolabile defect
(ISIS) Collaborators. Lancet, 355(9202), 434–442. of methylenetetrahydrofolate reductase in coronary artery disease.
118. Psaty, B. M., Smith, N. L., Lemaitre, R. N., et al. (2001). Hormone re- Circulation, 88(4, Pt. 1), 1463–1469.
placement therapy, prothrombotic mutations, and the risk of incident 139. Aouizerat, B. E., Allayee, H., Cantor, R. M., et al. (1999). A genome scan
nonfatal myocardial infarction in postmenopausal women. JAMA, for familial combined hyperlipidemia reveals evidence of linkage with a
285(7), 906–913. locus on chromosome 11. American Journal of Human Genetics, 65(2),
119. Le, W., Yu, J. D., Lu, L., et al. (2000). Association of the R485K poly- 397–412.
morphism of the factor V gene with poor response to activated protein 140. Bray, M. S., Krushkal, J., Li, L., et al. (2000). Positional genomic analy-
C and increased risk of coronary artery disease in the Chinese popula- sis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus
tion. Clinical Genetics, 57(4), 296–303. for human hypertension. Circulation, 101(25), 2877–2882.
7
7
120. Rosendaal, F. R., Siscovick, D. S., Schwartz, S. M., et al. (1997). Factor 141. Ghosh, S., Watanabe, R. M., Valle, T. T., et al. (2000). The
V Leiden (resistance to activated protein C) increases the risk of my- Finland–United States investigation of non-insulin-dependent diabetes
ocardial infarction in young women. Blood, 89(8), 2817–2821. mellitus genetics (FUSION) study. I. An autosomal genome scan for
121. Di Castelnuovo, A., D’Orazio, A., Amore, C., et al. (2000). The de- genes that predispose to type 2 diabetes. American Journal of Human
7
7
canucleotide insertion/deletion polymorphism in the promoter region of Genetics, 67(5), 1174–1185.
the coagulation factor VII gene and the risk of familial myocardial in- 142. Hein, L., Barsh, G. S., Pratt, R. E., et al. (1995). Behavioural and car-
farction. Thrombosis Research, 98(1), 9–17. diovascular effects of disrupting the angiotensin II type-2 receptor in
122. Feng, D., Tofler, G. H., Larson, M. G., et al. (2000). Factor VII gene mice. Nature, 377(6551), 744–747.
7
7
polymorphism, factor VII levels, and prevalent cardiovascular disease: 143. Krushkal, J., Ferrell, R., Mockrin, S. C., et al. (1999). Genome-wide
The Framingham Heart Study. Arteriosclerosis, Thrombosis, and Vascular linkage analyses of systolic blood pressure using highly discordant sib-
Biology, 20(2), 593–600. lings. Circulation, 99(11), 1407–1410.
123.Girelli, D., Russo, C., Ferraresi, P., et al. (2000). Polymorphisms in the fac- 144. Pajukanta, P., Cargill, M., Viitanen, L., et al. (2000). Two loci on chro-
tor VII gene and the risk of myocardial infarction in patients with coro- mosomes 2 and X for premature coronary heart disease identified in
nary artery disease. New England Journal of Medicine, 343(11), 774–780. early- and late-settlement populations of Finland. American Journal of
7
7
124. Green, F., Hamsten, A., Blomback, M., et al. (1993). The role of beta- Human Genetics, 67(6), 1481–1493.
fibrinogen genotype in determining plasma fibrinogen levels in young 145. Vionnet, N., Hani, E. H., Dupont, S., et al. (2000). Genomewide search
survivors of myocardial infarction and healthy controls from Sweden. for type 2 diabetes-susceptibility genes in French whites: Evidence for a
Thrombosis and Haemostasis, 70(6), 915–920. novel susceptibility locus for early-onset diabetes on chromosome 3q27-
125. Humphries, S. E., Panahloo, A., Montgomery, H. E., et al. (1997). qter and independent replication of a type 2-diabetes locus on chromo-
7
7
Gene-environment interaction in the determination of levels of haemo- some 1q21–q24. American Journal of Human Genetics, 67(6), 1470–1480.
static variables involved in thrombosis and fibrinolysis. Thrombosis and 146. Watanabe, R. M., Ghosh, S., Langefeld, C. D., et al. (2000). The Fin-
Haemostasis, 78(1), 457–461. land–United States investigation of non-insulin-dependent diabetes mel-
T
T
126. Tybjaerg-Hansen, A., Agerholm-Larsen, B., Humphries, S. E., et al. litus genetics (FUSION) study. II. An autosomal genome scan for dia-
S
S
(1997). A common mutation (G-455SA) in the beta-fibrinogen pro- betes-related quantitative-trait loci. American Journal of Human Genetics,
7
moter is an independent predictor of plasma fibrinogen, but not of is- 67(5), 1186–1200.
7
chemic heart disease. A study of 9,127 individuals based on the Copen- 147. Hines, L. M., Stampfer, M. J., Ma, J., et al. (2001). Genetic variation in
hagen City Heart Study. Journal of Clinical Investigations, 99(12), alcohol dehydrogenase and the beneficial effect of moderate alcohol con-
3034–3039. sumption on myocardial infarction. New England Journal of Medicine,
127. Yu, Q., Safavi, F., Roberts, R., et al. (1996). A variant of beta fibrinogen 344(8), 549–555.
is a genetic risk factor for coronary artery disease and myocardial infarc- 148. McCombs, R. J., Marcadis, D. E., Ellis, J., et al. (1994). Attenuated hy-
tion. Journal of Investigative Medicine, 44(4), 154–159. percholesterolemic response to a high-cholesterol diet in subjects het-
128. Pastinen, T., Perola, M., Niini, P., et al. (1998). Array-based multiplex erozygous for the apolipoprotein A-IV-2 allele. New England Journal of
analysis of candidate genes reveals two independent and additive genetic Medicine, 331(11), 706–710.
risk factors for myocardial infarction in the Finnish population. Human 149. Ordovas, J. M. (1999). The genetics of serum lipid responsiveness to di-
7
7
Molecular Genetics, 7(9), 1453–1462. etary interventions. Proceedings of the Nutrition Society, 58(1), 171–187.
129. Hooper, W. C., Lally, C., Austin, H., et al. (1999). The relationship be- 150. Tall, A., Welch, C., Applebaum-Bowden, D., et al. (1997). Interaction
tween polymorphisms in the endothelial cell nitric oxide synthase gene of diet and genes in atherogenesis. Report of an NHLBI working group.
7
and the platelet GPIIIa gene with myocardial infarction and venous Arteriosclerosis, Thrombosis, and Vascular Biology, 17(11), 3326–3331.
7
6
thromboembolism in African Americans. Chest, 116(4), 880–886. 151. Denke, M. A., Adams-Huet, B., & Nguyen, A. T. (2000). Individual
6
130. Ridker, P. M., Hennekens, C. H., Schmitz, C., et al. (1997). PIA1/A2 cholesterol variation in response to a margarine- or butter-based diet: A
polymorphism of platelet glycoprotein IIIa and risks of myocardial in- study in families. JAMA, 284(21), 2740–2747.
farction, stroke, and venous thrombosis. Lancet, 349(9049), 385–388. 152. Mirvis, D. M., & Chang, C. F. (1997). Managed care, managing uncer-
7
131. Weiss, E. J., Bray, P. F., Tayback, M., et al. (1996). A polymorphism of tainty. Archives of Internal Medicine, 157(4), 385–388.
7
a platelet glycoprotein receptor as an inherited risk factor for coronary 153. Summary of the second report of the National Cholesterol Education
thrombosis. New England Journal of Medicine, 334(17), 1090–1094. Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
132. Wenzel, K., Felix, S., Kleber, F. X., et al. (1994). E-selectin polymor- of High Blood Cholesterol in Adults (Adult Treatment Panel II). (1993).
phism and atherosclerosis: An association study. Human Molecular Ge- JAMA, 269(23), 3015–3023.
netics, 3(11), 1935–1937. 154. Effect of simvastatin on coronary atheroma: The Multicentre Anti-
133. Boers, G. H., Fowler, B., Smals, A. G., et al. (1985). Improved identifi- Atheroma Study (MAAS). (1994, September 3) Lancet, 344(8923),
cation of heterozygotes for homocystinuria due to cystathionine synthase 633–638.
deficiency by the combination of methionine loading and enzyme deter- 155. Randomised trial of cholesterol lowering in 4444 patients with coronary
mination in cultured fibroblasts. Human Genetics, 69(2), 164–169. heart disease: The Scandinavian Simvastatin Survival Study (4S). (1994).
134. Boers, G. H., Smals, A. G., Trijbels, F. J., et al. (1985). Heterozygosity Lancet, 344(8934), 1383–1389.
for homocystinuria in premature peripheral and cerebral occlusive arte- 156. Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., et al. (1993). Coro-
rial disease. New England Journal of Medicine, 313(12), 709–715. nary angiographic changes with lovastatin therapy. The Monitored Ath-
135. Franken, D. G., Boers, G. H., Blom, H. J., et al. (1996). Prevalence of erosclerosis Regression Study (MARS). Annals of Internal Medicine,
familial mild hyperhomocysteinemia. Atherosclerosis, 125(1), 71–80. 119(10), 969–976.
136. Christensen, B., Frosst, P., Lussier-Cacan, S., et al. (1997). Correlation of 157. Blankenhorn, D. H., Nessim, S. A., Johnson, R. L., et al. (1987). Bene-
a common mutation in the methylenetetrahydrofolate reductase gene ficial effects of combined colestipol-niacin therapy on coronary athero-
7
7
with plasma homocysteine in patients with premature coronary artery sclerosis and coronary venous bypass grafts. JAMA, 257(23),
7
disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 17(3), 569–573. 3233–3240.
7